From Wikipedia, the free encyclopedia
Chemical compound
DOV 216,303 is an experimental
antidepressant
drug originally developed by
DOV Pharmaceutical and was licensed to
Merck & Co. in 2004;
[1] Merck and DOV terminated their relationship in December 2006.
[2] : 12
[3]
It is a
triple reuptake inhibitor (TRI), or
serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI).
[4] It is the
racemic mixture of
amitifadine (DOV-21,947) and its (–)-
enantiomer ,
DOV-102,677 . Its
IC50 values for
SERT ,
NET , and
DAT are Ki 14 nM, 20 nM, and 78 nM, respectively.
[4]
As of March 2008, DOV had no intention to further develop DOV-216,303 because the patent on the compound had expired.
[2] : 6
In a
mouse model , DOV-216,303 has shown the ability to promote recovery after spinal cord
contusion .
[5]
See also
References
^ McCoy M (August 12, 2004).
"Merck and DOV Pharmaceutical In Drug Pact" . Chemical & Engineering News .
^
a
b
"10-K For the fiscal year ended December 31, 2007" . Dov Pharmaceutical via SEC Edgar. March 31, 2008. DOV 216,303 was originally in development for depression; however as the patented composition of matter claim has expired, there are no ongoing clinical trials of DOV 216,303 and none are planned.
^
"DOV 216303" . Adis Insight . Springer Nature Switzerland AG. Retrieved 26 February 2017 .
^
a
b Skolnick P, Krieter P, Tizzano J, Basile A, Popik P, Czobor P, Lippa A (2006).
"Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor" . CNS Drug Reviews . 12 (2): 123–34.
doi :
10.1111/j.1527-3458.2006.00123.x .
PMC
6494125 .
PMID
16958986 .
^ Chu TH, Cummins K, Stys PK (May 2018). "The triple monoamine re-uptake inhibitor DOV 216,303 promotes functional recovery after spinal cord contusion injury in mice". Neuroscience Letters . 675 : 1–6.
doi :
10.1016/j.neulet.2018.03.050 .
PMID
29578004 .
S2CID
5007186 .
SSRIs Tooltip Selective serotonin reuptake inhibitors
SNRIs Tooltip Serotonin–norepinephrine reuptake inhibitors
NRIs Tooltip Norepinephrine reuptake inhibitors
NDRIs Tooltip Norepinephrine–dopamine reuptake inhibitors
NaSSAs Tooltip Noradrenergic and specific serotonergic antidepressants
SARIs Tooltip Serotonin antagonist and reuptake inhibitors
SMS Tooltip Serotonin modulator and stimulators Others
TCAs Tooltip Tricyclic antidepressants
TeCAs Tooltip Tetracyclic antidepressants Others
Non-selective
MAOA Tooltip Monoamine oxidase A -selective
MAOB Tooltip Monoamine oxidase B -selective
DAT Tooltip Dopamine transporter (
DRIs Tooltip Dopamine reuptake inhibitors )
NET Tooltip Norepinephrine transporter (
NRIs Tooltip Norepinephrine reuptake inhibitors )
Others:
Antihistamines (e.g.,
brompheniramine ,
chlorphenamine ,
pheniramine ,
tripelennamine )
Antipsychotics (e.g.,
loxapine ,
ziprasidone )
Arylcyclohexylamines (e.g.,
ketamine ,
phencyclidine )
Dopexamine
Ephenidine
Ginkgo biloba
Indeloxazine
Nefazodone
Opioids (e.g.,
desmetramadol ,
methadone ,
pethidine (meperidine) ,
tapentadol ,
tramadol ,
levorphanol )
SERT Tooltip Serotonin transporter (
SRIs Tooltip Serotonin reuptake inhibitors )
Others:
A-80426
Amoxapine
Antihistamines (e.g.,
brompheniramine ,
chlorphenamine ,
dimenhydrinate ,
diphenhydramine ,
mepyramine (pyrilamine) ,
pheniramine ,
tripelennamine )
Antipsychotics (e.g.,
loxapine ,
ziprasidone )
Arylcyclohexylamines (e.g.,
3-MeO-PCP ,
esketamine ,
ketamine ,
methoxetamine ,
phencyclidine )
Cyclobenzaprine
Delucemine
Dextromethorphan
Dextrorphan
Efavirenz
Hypidone
Medifoxamine
Mesembrine
Mifepristone
MIN-117 (WF-516)
N-Me-5-HT
Opioids (e.g.,
dextropropoxyphene ,
methadone ,
pethidine (meperidine) ,
levorphanol ,
tapentadol ,
tramadol )
Roxindole
VMATs Tooltip Vesicular monoamine transporters Others